1. Home
  2. CRDL vs RPT Comparison

CRDL vs RPT Comparison

Compare CRDL & RPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRDL
  • RPT
  • Stock Information
  • Founded
  • CRDL 2017
  • RPT 2014
  • Country
  • CRDL Canada
  • RPT United States
  • Employees
  • CRDL N/A
  • RPT N/A
  • Industry
  • CRDL Biotechnology: Biological Products (No Diagnostic Substances)
  • RPT
  • Sector
  • CRDL Health Care
  • RPT
  • Exchange
  • CRDL Nasdaq
  • RPT NYSE
  • Market Cap
  • CRDL 112.4M
  • RPT 121.7M
  • IPO Year
  • CRDL N/A
  • RPT N/A
  • Fundamental
  • Price
  • CRDL $1.44
  • RPT $2.67
  • Analyst Decision
  • CRDL Strong Buy
  • RPT Strong Buy
  • Analyst Count
  • CRDL 2
  • RPT 1
  • Target Price
  • CRDL $9.00
  • RPT $4.00
  • AVG Volume (30 Days)
  • CRDL 289.4K
  • RPT 372.9K
  • Earning Date
  • CRDL 08-11-2025
  • RPT 07-24-2025
  • Dividend Yield
  • CRDL N/A
  • RPT 8.99%
  • EPS Growth
  • CRDL N/A
  • RPT N/A
  • EPS
  • CRDL N/A
  • RPT N/A
  • Revenue
  • CRDL N/A
  • RPT $8,096,000.00
  • Revenue This Year
  • CRDL N/A
  • RPT N/A
  • Revenue Next Year
  • CRDL N/A
  • RPT $19.21
  • P/E Ratio
  • CRDL N/A
  • RPT N/A
  • Revenue Growth
  • CRDL N/A
  • RPT N/A
  • 52 Week Low
  • CRDL $0.77
  • RPT $2.29
  • 52 Week High
  • CRDL $2.63
  • RPT $3.78
  • Technical
  • Relative Strength Index (RSI)
  • CRDL 56.90
  • RPT N/A
  • Support Level
  • CRDL $1.14
  • RPT N/A
  • Resistance Level
  • CRDL $1.42
  • RPT N/A
  • Average True Range (ATR)
  • CRDL 0.10
  • RPT 0.00
  • MACD
  • CRDL 0.01
  • RPT 0.00
  • Stochastic Oscillator
  • CRDL 83.33
  • RPT 0.00

About CRDL Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.

About RPT RITHM PROPERTY TRUST INC

Rithm Property Trust Inc is a real estate investment trust (REIT) externally managed by an affiliate of Rithm Capital Corp. (Rithm). The group is embarking on a new commercial real estate-focused investment. Its tailored approach to investment management seeks to generate attractive risk-adjusted returns for stockholders over the long term through dividends and capital appreciation.

Share on Social Networks: